How to Fight Insurance Denials for Endocrine Drugs (Testosterone, Tepezza, Cushing's, Acromegaly, CAH)

Endocrine disorders outside of diabetes—hypogonadism requiring testosterone replacement, Cushing's disease, acromegaly, congenital adrenal hyperplasia (CAH), thyroid eye disease (TED), hypoparathyroidism, and adult growth hormone deficiency—are rare, expensive to treat, and almost universally require specialty drugs. Because these medications often cost tens of thousands per year and lack generic alternatives, insurance companies deny them at extraordinarily high rates. Testosterone is denied for men with documented low testosterone because insurers claim a single test is insufficient or demand trials of cheaper generics first. Tepezza for thyroid eye disease, which can prevent blindness, is denied as "cosmetic." Crenessity for CAH, approved in December 2024, is labeled "experimental." Yorvipath for chronic hypoparathyroidism, approved in August 2024, is refused because insurers claim calcium and calcitriol pills are "adequate." The common thread: these denials are policy-driven, not medically sound, and they can be overturned with the right documentation and citations.

Why Insurers Deny Endocrine Treatments

1. Insufficient biochemical confirmation

Insurers demand strict diagnostic thresholds. For testosterone replacement therapy (TRT), plans require two morning (AM) total testosterone measurements below 300 ng/dL, often taken weeks apart and fasting. For Cushing's, they require two of three abnormal tests: 24-hour urinary free cortisol (UFC), late-night salivary cortisol, or low-dose dexamethasone suppression. For acromegaly, they want elevated IGF-1 and growth hormone (GH) failure to suppress below 1 ng/mL during an oral glucose tolerance test (OGTT). For adult growth hormone deficiency (AGHD), they require insulin tolerance test (ITT) or glucagon stimulation showing peak GH below 5 ng/mL. If you submit labs without meeting these exact criteria—one testosterone measurement, one Cushing's test, or IGF-1 without OGTT—expect a denial citing "not medically necessary."

2. "Step therapy": demand trials of cheaper alternatives first

Even when your diagnosis is confirmed, insurers require that you fail older, cheaper drugs before approving newer ones. For TRT, they may demand trials of generic testosterone cypionate or enanthate injections before covering newer formulations like Jatenzo (oral), Xyosted (auto-injector), or Aveed (long-acting). For Cushing's disease, they require failure of ketoconazole (generic, off-label, hepatotoxic) before approving Isturisa or Recorlev. For acromegaly, they require injectable somatostatin analogs (SSAs) like Sandostatin LAR or Somatuline Depot before oral Mycapssa, even if you have documented injection-site reactions or poor adherence. For CAH, they insist on maximizing glucocorticoids despite chronic over-replacement before approving Crenessity.

3. "Experimental or investigational" for newly approved drugs

Crenessity (crinecerfont) received FDA approval for classic congenital adrenal hyperplasia in December 2024. Yorvipath (palopegteriparatide) was approved for chronic hypoparathyroidism in August 2024. Despite FDA approval, insurers flag these as "experimental," "not proven," or "lacking long-term data." They cite internal medical policies written before the approval date or claim the drug is "under review." This is a stalling tactic: FDA approval is the gold standard, and Endocrine Society guidelines are updated to incorporate pivotal trial data within months.

4. "Cosmetic," "quality of life," or "not medically necessary" for symptom-driven indications

Tepezza (teprotumumab) for thyroid eye disease is denied as "cosmetic" when patients present with diplopia (double vision), proptosis (bulging eyes), and clinical activity scores (CAS) of 4 or higher out of 7. Insurers claim the condition is "self-limited" or that orbital decompression surgery is the appropriate first-line therapy—despite Tepezza being the only FDA-approved medical treatment proven to reduce proptosis and diplopia. Testosterone replacement is denied for men with confirmed low testosterone and severe symptoms (fatigue, sexual dysfunction, depression) because insurers claim symptoms are "subjective" or attributable to aging.

5. "Contraindication" or "safety concern" based on outdated criteria

For TRT, insurers deny coverage citing elevated hematocrit (>50%), "risk of prostate cancer," or cardiovascular concerns—often without reviewing recent labs or citing outdated 2014 FDA warnings later walked back. For Korlym (mifepristone) in Cushing's with hyperglycemia, they flag the drug's anti-progesterone activity and demand extensive contraceptive documentation. For Yorvipath, they claim chronic hypocalcemia is "managed" with calcium and calcitriol, ignoring hypercalciuria, nephrocalcinosis, recurrent ER visits for tetany, and poor quality of life.

The Citations Insurers Respect

When you appeal, cite specific, named clinical practice guidelines and pivotal trials. Do not paraphrase or summarize. Use the full title, author, journal, and year. Insurers' medical directors are required to defer to peer-reviewed evidence and specialty society guidelines.

Testosterone Replacement Therapy (TRT)

• Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men with Hypogonadism (2018) — Bhasin S et al., Journal of Clinical Endocrinology & Metabolism (JCEM) 2018. This is the load-bearing reference for TRT appeals. It specifies two morning total testosterone measurements below 300 ng/dL, evaluation for secondary causes (prolactin, TSH, ferritin, pituitary MRI if central hypogonadism), and assessment of symptoms using validated tools like the ADAM questionnaire.

Thyroid Eye Disease (TED)

• OPTIC trial — Douglas RS et al., New England Journal of Medicine (NEJM) 2020. Phase 3 trial establishing Tepezza efficacy for proptosis reduction.
• LINC-3 trial (also called HORIZON) — Referenced in FDA approval documents; double-blind, placebo-controlled trial demonstrating reduction in proptosis and clinical activity score (CAS) in active TED.
• Clinical activity score (CAS) ≥4 of 7 is the threshold for "active" disease requiring systemic therapy per American Thyroid Association and European Group on Graves' Orbitopathy (EUGOGO) guidelines.

Congenital Adrenal Hyperplasia (CAH)

• Endocrine Society Clinical Practice Guideline: Congenital Adrenal Hyperplasia (2018) — Speiser PW et al., JCEM 2018.
• CAHtalyst pivotal trials — Phase 3 trials of crinecerfont (Crenessity) published 2023–2024, demonstrating androgen reduction and glucocorticoid-sparing in classic CAH. FDA approval December 2024.

Cushing's Disease

• Endocrine Society Clinical Practice Guideline: Treatment of Cushing's Syndrome (2015) — Nieman LK et al., JCEM 2015. Specifies two of three abnormal screening tests (24-hour UFC, late-night salivary cortisol, overnight or low-dose dexamethasone suppression) to establish diagnosis.
• LINC-3 trial (osilodrostat/Isturisa) — Pivotal trial for Cushing's disease, published in Lancet Diabetes & Endocrinology 2020.
• SONICS trial (levoketoconazole/Recorlev) — Phase 3 trial for endogenous Cushing's syndrome, published JCEM 2020.

Acromegaly

• Endocrine Society Clinical Practice Guideline: Acromegaly (2014, updated 2018) — Katznelson L et al., JCEM.
• MPOWERED trial — Oral octreotide (Mycapssa) pivotal trial, published Lancet Diabetes & Endocrinology 2020, demonstrating non-inferiority to injectable SSAs in patients previously controlled on Sandostatin LAR or Somatuline Depot.

Chronic Hypoparathyroidism

• PaTHway trial — Pivotal phase 3 trial of palopegteriparatide (Yorvipath), published 2023. Demonstrated reduction in supplemental calcium and active vitamin D requirements, control of hypercalciuria, and improved quality of life.
• FDA approval August 2024 for chronic hypoparathyroidism.

Adult Growth Hormone Deficiency (AGHD)

• Endocrine Society Clinical Practice Guideline: Evaluation and Treatment of Adult Growth Hormone Deficiency (2019) — Yuen KCJ et al., Endocrine Practice 2019.
• REAL 2 trial (somapacitan/Sogroya) — Phase 3 trial of once-weekly growth hormone, published JCEM 2020.

How to Argue Against Each Denial Reason

"Insufficient biochemical confirmation"

If you were denied TRT for a single testosterone measurement:

1. Obtain a second morning total testosterone, ideally 7–11 AM, fasting, at least one week after the first. If both are below 300 ng/dL, you meet the Endocrine Society 2018 threshold.

2. Document secondary workup: measure LH, FSH, prolactin (to rule out prolactinoma), TSH (to rule out hypothyroidism), and ferritin (to screen for hemochromatosis). If LH and FSH are low or low-normal, order a pituitary MRI to rule out secondary hypogonadism.

3. Cite Bhasin et al. 2018 explicitly: "The Endocrine Society Clinical Practice Guideline (Bhasin S et al., JCEM 2018) requires two morning total testosterone measurements below 300 ng/dL, which this patient meets [date 1: X ng/dL, date 2: Y ng/dL]."

4. Include symptom validation: use the Androgen Deficiency in Aging Males (ADAM) questionnaire or similar validated tool.

If you were denied Cushing's treatment for incomplete testing:

1. Ensure you have two of three abnormal tests: 24-hour urinary free cortisol (UFC) elevated, late-night salivary cortisol elevated, or failure to suppress cortisol after low-dose dexamethasone (1 mg overnight or 2 mg over 48 hours).

2. Cite Nieman et al. 2015: "The Endocrine Society guideline for Cushing's Syndrome (Nieman LK et al., JCEM 2015) requires two abnormal screening tests for biochemical confirmation."

3. If ACTH is detectable or elevated and pituitary MRI shows adenoma, state "ACTH-dependent Cushing's disease confirmed by imaging."

If you were denied acromegaly treatment for IGF-1 alone:

1. Obtain an oral glucose tolerance test (OGTT) with growth hormone (GH) measured at baseline, 30, 60, 90, and 120 minutes. Failure to suppress GH below 1 ng/mL confirms acromegaly.

2. Cite Katznelson et al. 2014/2018: "Acromegaly diagnosis requires elevated age- and sex-adjusted IGF-1 and failure of GH suppression during OGTT per Endocrine Society guidelines."

"Step therapy: no trial of cheaper alternative"

For TRT denial demanding generic injectable testosterone first:

If you have a documented contraindication or intolerance to injections (e.g., needle phobia, bleeding disorder, injection-site abscess history), state it explicitly. If the insurer demands a trial anyway, ask your doctor to prescribe a short trial (4–8 weeks) of testosterone cypionate or enanthate, document side effects or non-adherence, then resubmit for the preferred formulation. Cite the Endocrine Society 2018 statement that "choice of formulation should be individualized based on patient preference, cost, and tolerability."

For Cushing's denial demanding ketoconazole first:

If you have contraindications (liver disease, QT prolongation, concomitant CYP3A4 inhibitors), state them. If you have already tried ketoconazole and developed hepatotoxicity (elevated ALT/AST) or failed to control cortisol, document the trial explicitly: "Patient trialed ketoconazole 400 mg twice daily for 3 months. ALT rose to 280 U/L (normal <40); drug discontinued. Isturisa is FDA-approved for Cushing's disease and has a superior safety profile (LINC-3 trial, Lancet Diabetes & Endocrinology 2020)."

For Mycapssa denial demanding injectable SSAs first:

If you have documented injection-site reactions (lipohypertrophy, pain, non-adherence due to injection burden), state it. Cite the MPOWERED trial: "Mycapssa (oral octreotide) demonstrated non-inferiority to injectable SSAs in the MPOWERED trial (Lancet Diabetes & Endocrinology 2020) for patients previously controlled on Sandostatin LAR or Somatuline Depot. This patient has documented [injection-site reactions / poor adherence / patient preference for oral therapy]."

"Experimental or investigational" for newly approved drugs

For Crenessity (crinecerfont) denied as experimental:

Cite the FDA approval date (December 2024) and the CAHtalyst trials: "Crenessity (crinecerfont) received FDA approval for classic congenital adrenal hyperplasia in December 2024 based on the CAHtalyst phase 3 trials. It is the first non-glucocorticoid therapy approved for CAH. This patient has genetically confirmed classic CAH (CYP21A2 mutation), elevated 17-hydroxyprogesterone and androstenedione despite maximized glucocorticoids, and meets FDA labeling criteria. Denial as 'experimental' contradicts FDA determination of safety and efficacy."

For Yorvipath (palopegteriparatide) denied as investigational:

Cite the FDA approval (August 2024) and the PaTHway trial: "Yorvipath received FDA approval for chronic hypoparathyroidism in August 2024 based on the PaTHway phase 3 trial. This patient has chronic hypoparathyroidism (low serum calcium, inappropriately low or normal PTH, confirmed [post-surgical / autoimmune / genetic etiology]), has required high-dose calcium (>2500 mg/day) and calcitriol (>1 mcg/day), has developed hypercalciuria (24-hour urine calcium >400 mg/day) and nephrocalcinosis on imaging, and has had [X] emergency room visits for hypocalcemic tetany in the past year. Conventional therapy has failed to provide adequate control."

"Cosmetic," "quality of life," or "not medically necessary"

For Tepezza denied for thyroid eye disease:

1. Document active disease: clinical activity score (CAS) ≥4 of 7. CAS assesses spontaneous orbital pain, gaze-evoked pain, eyelid swelling, eyelid redness, conjunctival injection, chemosis, and caruncle swelling. Have your ophthalmologist or endocrinologist complete the score at each visit.

2. Document functional impairment: diplopia (double vision) requiring prism glasses or patching, proptosis causing exposure keratopathy or corneal ulceration, compressive optic neuropathy (vision loss). Take serial photographs documenting proptosis.

3. Cite the OPTIC and LINC-3 (HORIZON) trials: "Tepezza is the only FDA-approved medical therapy for thyroid eye disease. The OPTIC trial (Douglas RS et al., NEJM 2020) and LINC-3 trial demonstrated significant reduction in proptosis (mean ~3 mm) and diplopia in patients with active TED (CAS ≥4). This patient has CAS of [X]/7, proptosis of [Y] mm, and diplopia limiting [driving / reading / work]. Tepezza is medically necessary to prevent permanent orbital changes and potential vision loss."

4. Rebut "cosmetic" claim: "Thyroid eye disease is a sight-threatening autoimmune condition. Proptosis and diplopia are functional impairments, not cosmetic concerns. Orbital decompression surgery is invasive, carries risks of permanent diplopia and vision loss, and is typically reserved for chronic, inactive disease. Tepezza is first-line therapy for active TED per American Thyroid Association guidelines."

For TRT denied for "subjective symptoms":

Use a validated symptom questionnaire (ADAM, Aging Males' Symptoms scale, or Sexual Health Inventory for Men). Document specific functional impairments: "Patient reports severe fatigue limiting ability to work full-time, loss of libido affecting marital relationship, and depressive symptoms (PHQ-9 score [X]). ADAM questionnaire positive (7 of 10). These symptoms are directly attributable to confirmed biochemical hypogonadism (total T <300 ng/dL on two occasions) and are expected to improve with testosterone replacement per Endocrine Society 2018 guidelines."

"Contraindication" or "safety concern"

For TRT denied citing cardiovascular risk or prostate cancer:

The 2018 Endocrine Society guideline states that testosterone replacement does not increase cardiovascular events in appropriately selected men and does not cause prostate cancer. If your hematocrit is elevated (>50%), state your plan: "Hematocrit will be monitored every 3 months. If it rises above 54%, testosterone dose will be reduced or phlebotomy performed per Endocrine Society guidelines. Patient has no history of prostate or breast cancer. PSA is [X] ng/mL (normal). Digital rectal exam is normal. Cardiovascular risk has been assessed; patient does not have uncontrolled heart failure or recent MI."

For Yorvipath denied due to "adequate control with calcium and calcitriol":

Document hypercalciuria (24-hour urine calcium >400 mg/day, ideally >300 mg/day), nephrocalcinosis or nephrolithiasis on renal ultrasound or CT, recurrent emergency room visits for hypocalcemic tetany or paresthesias, inability to maintain serum calcium in the low-normal range despite high-dose supplements, and poor quality of life (frequent dosing, GI side effects, pill burden). Cite the PaTHway trial: "Yorvipath reduced calcium and calcitriol requirements, improved hypercalciuria, and improved quality of life in patients with chronic hypoparathyroidism inadequately controlled on conventional therapy. This patient requires [X] mg calcium and [Y] mcg calcitriol daily, has 24-hour urine calcium of [Z] mg/day, and has had [X] ER visits in the past year."

What We Do

We are a specialized appeal service for patients denied coverage of endocrine therapies. We review your denial letter, clinical records, and lab results; identify which guidelines and trial data apply to your case; and draft physician-ready appeal letters citing the Endocrine Society, AACE, FDA approvals, and pivotal trials. We do not replace your endocrinologist—we provide the documentation and citations that medical directors respect. Most denials are overturned on first or second appeal when the right evidence is presented in the right format.

Sources

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

2. Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831.

3. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. (Updated 2018.)

4. Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocr Pract. 2019;25(11):1191-1232.

5. Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.

6. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341-352. (OPTIC trial.)

7. Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary. 2016;19(2):138-148. (LINC-3 preliminary; full trial Lancet Diabetes Endocrinol. 2020.)

8. Samson SL, Gu F, Feldt-Rasmussen U, et al. Once-weekly somapacitan vs. daily GH in adults with GH deficiency: the REAL 2 randomized clinical trial. J Clin Endocrinol Metab. 2022;107(1):e92-e104.

9. Gilis-Januszewska A, Jedrzejuk D, Nikolajuk A, et al. Chronic Hypoparathyroidism—Current Challenges in Diagnosis and Treatment. J Clin Med. 2021;10(16):3605. (Reviews PaTHway trial data.)

10. Samson SL, Ezzat S,Ififita P, et al. Oral octreotide for acromegaly: results from the phase 3 MPOWERED study. Lancet Diabetes Endocrinol. 2020;8(10):748-760. (MPOWERED trial.)

11. U.S. Food and Drug Administration. FDA approves first treatment for congenital adrenal hyperplasia. December 2024. (Crenessity/crinecerfont approval.)

12. U.S. Food and Drug Administration. FDA approves new treatment for chronic hypoparathyroidism. August 2024. (Yorvipath/palopegteriparatide approval.)